Imatinib Koanaa 100 Mg (Imatinib Mesilate)

Imatinib mesilate blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug stops the signaling pathways that promote uncontrolled cell division, leading to reduced proliferation of malignant cells in the indicated cancers.

The exact dose of Imatinib Koanaa is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant medications. Dosage adjustments are made to balance efficacy with safety, and patients should follow the prescriber’s written instructions.

Safety data for Imatinib Koanaa in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Imatinib Koanaa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first targeted BCR‑ABL inhibitor and remains a standard first‑line therapy for chronic phase CML. Newer agents such as dasatinib and nilotinib offer alternative potency and side‑effect profiles, but Imatinib’s long‑term safety record and extensive clinical experience make it a widely accepted option, especially where cost considerations are important.

Imatinib Koanaa tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister or container, protect from moisture and direct light, and ensure the packaging remains tightly closed until use.

Imatinib Koanaa is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include severe neutropenia or leukopenia, thrombocytopenia, hepatotoxicity, cardiac failure, pulmonary hypertension, and rare but life‑threatening hemorrhage. Patients should report signs of infection, unusual bruising, yellowing of the skin or eyes, shortness of breath, or swelling of the legs to their healthcare provider promptly.

Imatinib Koanaa is contraindicated in patients with known hypersensitivity to imatinib mesilate or any of the tablet excipients. It should be used with caution, or avoided, in individuals with severe hepatic impairment, uncontrolled cardiac disease, or active infections, and only after a thorough risk‑benefit assessment by a qualified clinician.